News & Events

KRAS G12S Positive Non-Small Cell Lung Cancer Mimicking KRAS G12C Positivity on the AmoyDx PCR Panel: A Case Report

KRAS G12S Positive Non-Small Cell Lung Cancer Mimicking KRAS G12C Positivity on the AmoyDx PCR Panel: A Case Report

VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors

VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors

Verastem's KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

Verastem's KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study

Herbert Loong: KRAS G12C in Asia, and Why the Landscape Still Matters

Herbert Loong: KRAS G12C in Asia, and Why the Landscape Still Matters

Trethera wins Fast Track for dCK inhibitor TRE-515 in KRAS G12C lung cancer combination

Trethera wins Fast Track for dCK inhibitor TRE-515 in KRAS G12C lung cancer combination

FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC

FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC

FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC

FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC